Point-of-care biochemistry for primary healthcare in low-middle income countries: a qualitative inquiry.

Point-of-care biochemistry for primary healthcare in low-middle income countries: a qualitative inquiry.

Publication date: Oct 11, 2024

Access to essential diagnostics is crucial for primary healthcare (PHC) in low-and-middle income countries (LMICs). Many LMICs have invested in equipping PHC with point-of-care (PoC) diagnostics for infectious diseases, however there has been no similar investment to improve PHC capacities for clinical chemistry. The biochemistry gap is among the deterrents to universal health coverage. A social sciences project was conducted with the aim to understand the key PHC stakeholders’ insights on the pertinence of PoC biochemistry for PHC in LMICs. Data generation was conducted between July-November 2023 in Mongolia, Nigeria and Peru. Decision-makers in healthcare delivery, healthcare professionals, and patient and community advocates were engaged using a combination of sampling techniques. Unstructured individual and group conversations, and non-participant observation were conducted. Analysis involved an inductive line-by-line coding on printed transcripts, followed by a deductive coding and theme-by-theme analysis on digitized transcripts. Fifteen, 51 and 20 informants from Mongolia, Nigeria and Peru, respectively, participated. Fifty-five of the 94 informants were female. Most informants considered that PoC biochemistry in PHC would be pertinent, from a clinical and a resources-saving perspective. Those households that currently bear the burden of referrals (i. e., the poor, the bedridden, the older adults) would benefit the most from the deployment of PoC biochemistry for essential biochemistry parameters. Improved access to PoC glycated hemoglobin (HbA1c), lipid, liver and kidney profile was perceived as helpful to inform clinicians’ decision-taking. The value of PoC biochemistry for the management of noncommunicable diseases (diabetes, hypertension) and infectious conditions (dengue, malaria, tuberculosis), to improve child health outcomes (severe dehydration in children with diarrhea and/or malnutrition) and to reduce preventable causes of death (dengue-related renal failure) was highlighted. PoC biochemistry holds potential to revert the impact that the biochemistry gap has for patient care in some LMICs’ PHC settings. PoC equipment for parameters such as HbA1c, urea, creatinine or electrolytes could enhance community-level management of preventable causes of mortality, improve service delivery for patients affected by locally-prevalent infectious conditions, and improve the psychosocial and economic wellbeing of patients facing the burden of referrals to remote biochemistry-equipped centers. Not applicable.

Open Access PDF

Concepts Keywords
Biochemistry Adult
Diabetes Biochemistry
Informants Clinical chemistry
July Developing Countries
Mongolia Female
Humans
Laboratory capacities
Low-middle income countries
Male
Mongolia
Nigeria
Noncommunicable diseases
Peru
Point-of-Care Systems
Point-of-Care Testing
Primary care strengthening
Primary Health Care
Primary healthcare system
Qualitative Research
Qualitative research

Semantics

Type Source Name
disease MESH infectious diseases
disease MESH noncommunicable diseases
disease MESH hypertension
disease MESH dengue
disease MESH malaria
pathway KEGG Malaria
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH dehydration
disease MESH malnutrition
disease MESH causes of death
disease MESH renal failure
drug DRUGBANK Urea
drug DRUGBANK Creatinine
disease MESH causes
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH death
disease IDO quality
drug DRUGBANK Serine
disease MESH COVID 19 pandemic
drug DRUGBANK Hexocyclium
disease MESH emergency
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Potassium
disease MESH hepatitis
disease MESH virus infection
drug DRUGBANK Etoperidone
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Trestolone
disease MESH breast cancer
pathway KEGG Breast cancer
drug DRUGBANK Trihexyphenidyl
disease IDO site
drug DRUGBANK Glutamic Acid
disease MESH chronic diseases
disease IDO role
disease MESH hypercholesterolemia
disease MESH infections
disease IDO country
disease MESH obesity
disease MESH hyperlipidemia
disease MESH radiculopathies
disease MESH osteoarthrosis
disease MESH lost to follow up
disease MESH polycystic ovary syndrome
disease MESH goiter
disease MESH viral hemorrhagic fevers
drug DRUGBANK Potassium Chloride
disease MESH Lassa fever
disease MESH jaundice
disease MESH Neurocysticercosis
disease MESH anemia
drug DRUGBANK Praziquantel
disease IDO blood
disease MESH severe dengue
drug DRUGBANK Alkaline Phosphatase
disease MESH proteinuria
drug DRUGBANK Cholesterol
disease MESH Congenital hypothyroidism
disease MESH metabolic diseases
disease MESH hypothyroidism
disease MESH mental retardation
disease MESH hyperthyroidism
disease MESH kwashiorkor
disease MESH marasmus
disease MESH hypokalemia
disease MESH hyponatremia
drug DRUGBANK Follitropin
drug DRUGBANK Testosterone
disease MESH Pre eclampsia
drug DRUGBANK Liothyronine
disease MESH infarcts
drug DRUGBANK Water
disease MESH gastritis
disease MESH pancreatitis
disease MESH prostate cancer
pathway KEGG Prostate cancer
disease MESH hyperplasia
disease MESH eclampsia
disease MESH syphilis
disease MESH zoonotic diseases
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Aspartame
disease IDO immunodeficiency
drug DRUGBANK L-Isoleucine
disease MESH Viral load
disease MESH community transmission
disease IDO facility
disease MESH chronic hepatitis
disease IDO infection
disease MESH liver disease
disease MESH Otitis Media
disease MESH Cleft Palate
drug DRUGBANK Gold
disease MESH pregnancy outcomes
drug DRUGBANK Guanosine
disease MESH diabetes mellitus

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *